• Eltanexor (KPT-8602): Beyond Nuclear Export—Pathways, Pre...

  2025-10-21

  Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, offers unique advantages for cancer research by targeting nuclear export and modulating key signaling pathways. Discover how its advanced mechanism and emerging applications in hematological and solid tumor studies set it apart from other nuclear export inhibitors.

• Eltanexor: Next-Gen XPO1 Inhibitor for Cancer Research Wo...

  2025-10-20

  Eltanexor (KPT-8602) redefines cancer research by offering a potent, orally bioavailable XPO1 inhibitor that excels in both hematological and solid tumor models. Explore advanced experimental workflows, troubleshooting strategies, and mechanistic insights that set Eltanexor apart as a transformative tool for targeting the nuclear export pathway in cancer.

• Pemetrexed: Advanced Antifolate Workflows in Cancer Research

  2025-10-19

  Pemetrexed’s multi-targeted antifolate mechanism unlocks precision in disrupting nucleotide biosynthesis, offering researchers a dynamic tool to probe tumor cell vulnerabilities. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights for deploying pemetrexed in non-small cell lung carcinoma and malignant mesothelioma models.

• Eltanexor: Advancing XPO1 Inhibitor Applications in Cance...

  2025-10-18

  Eltanexor (KPT-8602) is redefining cancer research with its potent, oral inhibition of XPO1—unlocking new strategies in both hematological and solid tumor studies. This article translates cutting-edge bench findings into actionable protocols, highlights comparative advantages over earlier nuclear export inhibitors, and delivers troubleshooting tips for optimizing experimental outcomes.

94 records 7/7 page Previous First page 上5页 67